Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1948 1
1949 1
1950 1
1958 1
1960 2
1962 6
1964 1
1965 2
1966 3
1967 5
1968 4
1969 7
1970 10
1971 12
1972 15
1973 17
1974 7
1975 11
1976 8
1977 24
1978 15
1979 15
1980 13
1981 13
1982 19
1983 25
1984 29
1985 40
1986 42
1987 50
1988 55
1989 74
1990 68
1991 70
1992 83
1993 118
1994 102
1995 147
1996 166
1997 206
1998 258
1999 310
2000 484
2001 469
2002 579
2003 662
2004 849
2005 998
2006 1151
2007 1450
2008 1761
2009 2057
2010 2428
2011 2935
2012 3216
2013 3483
2014 3656
2015 3778
2016 3839
2017 4042
2018 4260
2019 4380
2020 4880
2021 5320
2022 4856
2023 4832
2024 4935
2025 1240

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66,218 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. Among authors: park sh. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution.
Hsu AY, Huang Q, Pi X, Fu J, Raghunathan K, Ghimire L, Balasubramanian A, Xie X, Yu H, Loison F, Haridas V, Zha J, Liu F, Park SY, Bagale K, Ren Q, Fan Y, Zheng Y, Cancelas JA, Chai L, Stowell SR, Chen K, Xu R, Wang X, Xu Y, Zhang L, Cheng T, Ma F, Thiagarajah JR, Wu H, Feng S, Luo HR. Hsu AY, et al. Among authors: park sy. Cell. 2025 Feb 11:S0092-8674(25)00050-9. doi: 10.1016/j.cell.2025.01.021. Online ahead of print. Cell. 2025. PMID: 39938514
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Among authors: park sh. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Free article. Clinical Trial.
Retinoic acid and TGF-β orchestrate organ-specific programs of tissue residency.
Obers A, Poch T, Rodrigues G, Christo SN, Gandolfo LC, Fonseca R, Zaid A, Kuai JEY, Lai H, Zareie P, Yakou MH, Dryburgh L, Burn TN, Dosser J, Buquicchio FA, Lareau CA, Walsh C, Judd L, Theodorou MR, Gutbrod K, Dörmann P, Kingham J, Stinear T, Kallies A, Schroeder J, Mueller SN, Park SL, Speed TP, Satpathy AT, Phan TG, Wilhelm C, Zaph C, Evrard M, Mackay LK. Obers A, et al. Among authors: park sl. Immunity. 2024 Nov 12;57(11):2615-2633.e10. doi: 10.1016/j.immuni.2024.09.015. Epub 2024 Oct 14. Immunity. 2024. PMID: 39406245
MicroRNA-19b exacerbates systemic sclerosis through promoting Th9 cells.
Lim YJ, Park SA, Wang D, Jin W, Ku WL, Zhang D, Xu J, Patiño LC, Liu N, Chen W, Kazmi R, Zhao K, Zhang YE, Sun L, Chen W. Lim YJ, et al. Among authors: park sa. Cell Rep. 2024 Aug 27;43(8):114565. doi: 10.1016/j.celrep.2024.114565. Epub 2024 Jul 30. Cell Rep. 2024. PMID: 39083380 Free PMC article.
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
Lee CK, Kim HS, Jung M, Kim H, Bae WK, Koo DH, Jeung HC, Park SR, Hwang IG, Zang DY, Lee HW, Park S, Nam CM, Chung HC, Rha SY. Lee CK, et al. Among authors: park sr, park s. J Clin Oncol. 2024 Jan 20;42(3):348-357. doi: 10.1200/JCO.23.00971. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883723 Clinical Trial.
66,218 results
You have reached the last available page of results. Please see the User Guide for more information.